TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06014983

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous fumarate
Description: Participants will supplement with 24 mg elemental iron in the form of ferrous fumarate daily for a minimum of 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous bisglycinate
Description: Participants will supplement with 24 mg elemental iron in the form of ferrous bisglycinate daily for a minimum of 12 weeks.
Study: NCT04566666

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of SCD-044 product
Study: NCT04842435

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In a Stage 1 study, Placebo is administered to clinical study subjects randomized to groups 4 by intravenous drip at a dose of 1 mL/kg.~The initial drug administration rate is from 0.01 mL/kg to 0.02 mL/kg of body weight per minute for 30 minutes. If the drug is well tolerated, the rate of administration can be gradually increased to a maximum of 0.12 mL/kg of body weight per minute. In order to control the drug administration rate, infusion shall be performed with an infusion pump.~In a Stage 2 study, placebo is administered to clinical study subjects randomized to group 2 by intravenous drip at a dose equal to the study drug dose.
Study: NCT06343532

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SXC-2023 Placebo
Description: 200 mg capsules
Study: NCT06571968

Intervention type: DEVICE
Group type: OTHER
Intervention: fully guided stent
Description: The guides were designed with metal sleeves for guided drilling and guided implant placement and additional guide sleeves for the stabilization of the template by fixation screws. All surgical procedures with drills were done thiough the stent.

Intervention type: DEVICE
Group type: OTHER
Intervention: fully guided stent
Description: The guides were designed with metal sleeves for guided drilling and guided implant placement and additional guide sleeves for the stabilization of the template by fixation screws. All surgical procedures with drills were done thiough the stent.
Study: NCT06019728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGALSIDASE BETA (GZ419828)
Description: Pharmaceutical form: Lyophilized powder for reconstitution Route of administration: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Tablet or solution; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Tablet or solution; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablet or solution; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Tablet or chewable tablet or oral granules; Oral
Study: NCT06001775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Priorities Care
Description: According to patientprioritiescare.org a Patient Priorities Care conversation helps to align healthcare decision-making and care by all clinicians with patients' own health priorities. Patient Priorities Care involves not only the health outcome goals that patients want to achieve, but also their preferences for healthcare.
Study: NCT06129734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is a BCL2 inhibitor. It is administered at low doses and used in combination with other hypomethylating agents such as decitabine to manage participants with acute myeloid lymphoma who have undergone stem cell transplant. Participants will initiate therapy with decitabine that will be followed by venetoclax 400 mg oral 6-8 hours later. Participants will continue this dose each week. The venetoclax dose will be reduced to 100 mg once per week if the participant is being treated with posaconazole or voriconazole (strong CYP3A4 inhibitors) (considered dose equivalent to venetoclax 400 mg 1X/week). The venetoclax dose will be reduced 200 mg once per week if the participant is being treated with fluconazole or isavuconazole (moderate CYP3A4 inhibitors) (considered dose equivalent to venetoclax 400 mg 1X/week). This clinical trial is administering venetoclax well below the current FDA approved dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is a hypomethylating agent. It is administered at low doses and used in combination with venetoclax to manage participants with acute myeloid lymphoma who have undergone stem cell transplant. Participants initiate therapy with 5 mg/m2 decitabine subcutaneous every week followed by venetoclax.
Study: NCT04566666

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCD-044_Dose 1
Description: SCD-044 tablets in Dose 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCD-044_Dose 2
Description: SCD-044 tablets in Dose 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCD-044_Dose 3
Description: SCD-044 in Dose 3
Study: NCT05142189

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT116
Description: intravenous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT116
Description: intravenous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT116
Description: intravenous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT116
Description: intravenous injection
Study: NCT06133712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Patients will receive injection of 1 microgram/kg dexmedetomidine average (70-100-microgram) (0.7-1ml) plus 4ml lidocaine injection nearby median nerve.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozone
Description: Participants will receive a single local injection of 4 ml ozone (10 micrograms/dl) plus to 1 ml lidocaine (1%) using a 25 G needle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients will receive a single local injection of 5 mL (3 mL lidocaine (1%) and 2 mL \[8 mg\] dexamethasone) via the same technique.
Study: NCT05019521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Oral tablet.
Study: NCT05064345

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HB0034
Description: Recombinant Humanized Anti-IL-36R Monoclonal antibody

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HB0034
Description: Recombinant Humanized Anti-IL-36R Monoclonal antibody

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HB0034
Description: Recombinant Humanized Anti-IL-36R Monoclonal antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Palcebo
Study: NCT05575804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GQ1001+pyrotinib
Description: GQ1001 infusions on day 1 of each 21-day cycle combinate with pyrotinib 320mg orally once daily until disease progression or unacceptable toxicity. I.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pyrotinib+capecitabine
Description: pyrotinib 400mg orally once daily in combination with capecitabine 1000mg/m2 twice daily, day1-14, every three weeks until disease progression or unacceptable toxicity.
Study: NCT05477238

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: walking tasks
Description: The experiment will be divided in two sessions. In the first session, the participant/healthy volunteers will do 3 walking tasks (over ground walking/ climbing up, down stairs). In the second session, the participant will walk outside in front of the hospital (walking on a slope, walking down, walking on uneven ground). All those tasks will be done while wearing a gas exchange analyzer, accelerometer and a heart rate meter.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: walking tasks
Description: The experiment will be divided in two sessions. In the first session, the participant/healthy volunteers will do 3 walking tasks (over ground walking/ climbing up, down stairs). In the second session, the participant will walk outside in front of the hospital (walking on a slope, walking down, walking on uneven ground). All those tasks will be done while wearing a gas exchange analyzer, accelerometer and a heart rate meter.
Study: NCT05534334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solu-Cortef
Description: A vial sol. used for intra-mascular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solu-Cortef
Description: A vial sol. used for intra-mascular injection
Study: NCT05019521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Oral tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Danicopan
Description: Oral tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet.
Study: NCT06059118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFMO
Description: Each 119 day cycle, Days 1-7 patient will take 1000 mg by mouth (PO) twice a day (bid), and then on Day 8 - 63 patient will take 1000 mg PO bid while receiving high dose testosterone IM on Day 8 and Day 36 of cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone cypionate
Description: On Day 8 and Day 36 of each 119 day cycle, patient will receive high dose testosterone at 400 mg through intramuscular (IM) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteinizing hormone-releasing hormone (LHRH) analogue
Description: Patients who have progressive disease after treatment with Abiraterone (Abi) will continue with androgen depravation therapy (ADT) with LHRH analogue (LHRH agonist drug (i.e. Zoladex, Trelstar, Eligard or Lupron) or LHRH antagonist drug (Degarelix or Relugolix)). Dosing instructions will vary between the different LHRH analogues. Patients should follow the dosing instructions as directed by their physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Each 119 day cycle, Days 64-119 patient will take 160 mg by mouth (PO) once a day (qd).
Study: NCT05878561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan + Indapamide
Description: a fixed dose combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan + Indapamide placebo
Description: a fixed dose combination
Study: NCT06571409

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coriander Seed Oil - Dose 1
Description: The study foresees the intake of 1 capsule per day during 56 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coriander Seed Oil - Dose 2
Description: The study foresees the intake of 1 capsule per day during 56 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study foresees the intake of 1 capsule per day during 56 days
Study: NCT05827263

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: T-Scan occlusal recording No. I
Description: Occlusal information was obtained using the T-Scan device before the main intervention. This process was repeated three times to confirm the findings.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: T-Scan occlusal recording No. I
Description: Occlusal information was obtained using the T-Scan device before the main intervention. This process was repeated three times to confirm the findings.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usage of the hydrostatic appliance
Description: The hydrostatic appliance was removed from its packaging and placed symmetrically between the upper lip and the oral vestibule of the maxilla for the most comfortable position. After 30 minutes, the hydrostatic appliance was removed, and patients were asked to keep their mouths open until the T-Scan was positioned correctly.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Usage of the hydrostatic appliance
Description: The hydrostatic appliance was removed from its packaging and placed symmetrically between the upper lip and the oral vestibule of the maxilla for the most comfortable position. After 30 minutes, the hydrostatic appliance was removed, and patients were asked to keep their mouths open until the T-Scan was positioned correctly.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: T-Scan occlusal recording No. II
Description: The occlusal registration was repeated three times using the T-Scan device in order to confirm the findings.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: T-Scan occlusal recording No. II
Description: The occlusal registration was repeated three times using the T-Scan device in order to confirm the findings.
Study: NCT04863131

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EXG-5003
Description: COVID-19 self-replicating mRNA vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo solution
Study: NCT04484740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Single oral dose of 1500 mg gepotidacin
Study: NCT06405815

Intervention type: OTHER
Intervention: tumor and peritumor radiomic feature
Description: extracted the tumor and peritumor radiomic feature from the preoperative enhanced chest CT
Study: NCT05214027

Intervention type: OTHER
Intervention: Treadmill-Based Exercise (60% VO2 Max for 60 minutes)
Description: Each participant will undergo a single 60-minute treadmill-based exercise intervention in a randomised order.~Treadmill settings are generated based on settings which correspond to participants exercising at 60% VO2 max from their maximal exercise test on visit 2. To confirm that participants are exercising at 60% during the hour session, 1 minute samples of expired air are taken at 15 minute intervals and immediately analysed to check % VO2 max. Participants heart rate and RPE measures are also taken at 15 minute intervals throughout the exercise session and cross-checked against predicted values at 60% VO2 Max.

Intervention type: OTHER
Intervention: Rest (60 minutes)
Description: Each participant will undergo a 60-minute rest period in a randomised order.
Study: NCT05675293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IONTOPHORESIS
Description: The process of increasing the penetration of drugs into the skin by application of an electric current
Study: NCT04475315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Papillary Muscle Sling
Description: The sling is made of a Gore-Tex sheet or by using a 4 mm Gore-Tex vascular graft implanted around the base of the papillary muscles and tightened.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG surgery
Description: Standard of care Coronary Artery Bypass Grafting (CABG) surgery will be performed to improve blood flow to the heart by bypassing the narrowed segment of a severely diseased coronary artery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CABG surgery
Description: Standard of care Coronary Artery Bypass Grafting (CABG) surgery will be performed to improve blood flow to the heart by bypassing the narrowed segment of a severely diseased coronary artery
Study: NCT05675293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ORAL ANTIBIOTIC
Description: Oral Antibiotic
Study: NCT06149962

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FLEXOR TENDON REPAIR
Description: we will repair tendon of FDP only using 6 strand technique using PDS 4/0 core suture - prolene 6/0 running suture under WALANT technique and brachial plexus block.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FLEXOR TENDON REPAIR
Description: we will repair tendon of FDP only using 6 strand technique using PDS 4/0 core suture - prolene 6/0 running suture under WALANT technique and brachial plexus block.
Study: NCT06123754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection
Description: The subjects receive Envafolimab/placebo treatment with a dosage of 600 mg/3 ml subcutaneously injected every 3 weeks.It will last about 3-4 cycles before surgery and 16 cycles after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection
Description: The subjects received platinum-based doublet chemotherapy on day 1 of every cycle. It's 3 weeks per cycle and lasts 3-4 cycles before surgery.
Study: NCT05223608

Intervention type: OTHER
Group type: OTHER
Intervention: ImmuCCo Cohort
Description: Blood sampling at initiation of immunotherapy, at the first tumor assessment, in case of severe toxicity. Urine collection at initiation of immunotherapy.
Study: NCT05416424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LIFE program
Description: During the nutritionist visits, subjects will be asked to discuss and evaluate their current diet and will be given recommended dietary changes. The recommended dietary changes include focusing on eating nutrient dense foods, staying consistent with the timing of meals, limiting added sugars, aiming to have balanced meals and snacks, being a mindful eater, and aiming to drink approximately 2 liters of water a day. Additionally, they will review the nutrition survey with the registered dietician. During the office visits with a doctor, subjects will be given exercise counseling. They will be asked to do 150 minutes per week of moderate intensity aerobic activity
Study: NCT05128032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard microcatheter
Description: Small device used for mapping as part of radioembolization procedure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard microcatheter
Description: Small device used for mapping as part of radioembolization procedure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEDD device
Description: Pressure enabled small device used for mapping as part of radioembolization procedure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEDD device
Description: Pressure enabled small device used for mapping as part of radioembolization procedure
Study: NCT05392322

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-help skills
Description: Self-help skills were given to down's syndrome children 3 times per week upto 15 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual video reality gaming
Description: Virtual video reality gaming was given to children with down's Syndrome 3 time per week upto 15 minutes.
Study: NCT06293898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M07D1
Description: Drug: BL-M07D1 The study includes 3 parts: Part 1 Dose escalation. Part 2 Dose Finding non-randomized and Part 3 Dose expansion randomized.
Study: NCT06220344

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Honey Dressing
Description: Honey Dressing will be applied from the 1st Post-Op day till the fully healed wound, which is described as no dehiscence, no exudate, no warmth, and sutures removed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodine Dressing
Description: Iodine Dressing will be applied from the 1st Post-Op day till the fully healed wound, which is described as no dehiscence, no exudate, no warmth, and sutures removed.
Study: NCT05437029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q-Griffithsin 3.0
Description: This is an open-label dose-escalation study to assess the safety, tolerability, and pharmacokinetics (PK) of a multiple dosing schedule of low dose Q GRFT intranasal spray DP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q-Griffithsin 6.0
Description: This is an open-label dose-escalation study to assess the safety, tolerability, and pharmacokinetics (PK) of a multiple dosing schedule of high dose Q GRFT intranasal spray DP
Study: NCT05835596

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Access to MumCare app
Description: Education, push warning to book cardiovascular health follow-up at own general practitioner , registration of BP and lipids, HbAc
Study: NCT05522829

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01E-1 on D0
Description: Day 0; intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01E-1 on D0
Description: Day 0; intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01E-1 on D28
Description: Day 28; intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01E-1 on D150
Description: Day 150; intramuscular injection
Study: NCT06007430

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colostrum Capsule 500 mg (Colostrum® 500 mg Veg Capsules, nowfoods®, Illinois, USA)
Description: Brand name: (Colostrum® 500 mg Veg Capsules) capsules per oral / once daily / 60 days duration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colostrum Capsule 500 mg (Colostrum® 500 mg Veg Capsules, nowfoods®, Illinois, USA)
Description: Brand name: (Colostrum® 500 mg Veg Capsules) capsules per oral / once daily / 60 days duration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule / Capsules per oral / once daily / 60 days duration
Study: NCT05522829

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SCTV01E on D0
Description: Day 0; intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SCTV01E on D0
Description: Day 0; intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SCTV01E on D28
Description: Day 28; intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SCTV01E on D150
Description: Day 150; intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01E-1 on D120
Description: Day 120; intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SCTV01E on D120
Description: Day 120; intramuscular injection
Study: NCT05483400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab and atezolizumab
Description: three weekly tiragolumab 1200 mg intravenous plus tiragolumab 600 mg intravenous.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab and atezolizumab
Description: three weekly tiragolumab 1200 mg intravenous plus tiragolumab 600 mg intravenous.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab and atezolizumab
Description: three weekly tiragolumab 1200 mg intravenous plus tiragolumab 600 mg intravenous.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab and atezolizumab
Description: three weekly tiragolumab 1200 mg intravenous plus tiragolumab 600 mg intravenous.